This study examined the risk of secondary cancers among patients with CML who were treated with TKIs.
Hodgkin lymphoma survivors are at higher risk of second cancers, and that risk is even higher in those with a first-degree relative with cancer.
Nearly 1 in 12 patients with a cancer from the 10 most common cancer sites developed a second primary neoplasm during survivorship.
Review found increased odds for developing thyroid or breast cancer as secondary malignancy after the other cancer type was diagnosed.
Lifelong screening is recommended for survivors of childhood cancer that affects the vision, in order to detect issues early.
Hodgkin lymphoma survivors have an increased risk of secondary cancer compared with the general population, even for those receiving more recent treatments.
The discovery of an enzyme that facilitates the spread of breast cancer may enable clinicians to prevent secondary cancer.
[Cancer Management and Research] Secondary cancer risk following radiotherapy is an increasingly important topic in clinical oncology with impact on treatment decision making and on patient management.
Compared to patients who were treated with surgery alone
A higher obesity-driven risk of secondary cancer has been identified for kidney, pancreatic, esophageal, endometrial cancers.
A new analysis has found that adolescents and young adults who develop thyroid cancer as a secondary cancer have a significantly greater risk of dying than those with primary thyroid cancer.
Girls treated for Hodgkin's lymphoma during adolescence acquire a considerable risk of developing breast cancer.
Patients with early-stage breast cancer who receive external beam therapy are not at higher risk for serious long-term side effects in the chest area.
A new study provides the first direct evidence that the deadly epithelial-to-mesenchymal transition occurs in humans during metasis, at least in patients with ovarian cancer.
Enhanced treatment and surveillance needed to prevent secondary cancers for certain melanoma patientsAugust 29, 2013
Secondary cancers seen in melanoma patients who are being treated for a BRAF gene mutation may require new strategies, such as enhancing surveillance and combining BRAF-inhibitor therapy with other inhibitors.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|